BDX vs IRMD
BDX: A global medical technology leader providing essential healthcare supplies, diagnostic systems, and biosciences research tools to improve patient outcomes. IRMD: IRADIMED CORP provides specialized MRI-compatible medical devices, specifically infusion pumps and patient monitoring systems, engineered for safe operation within magnetic resonance imaging environments.
Side-by-side fundamentals
| Metric | BDX | IRMD | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $194.34 | $87.81 | |
| Market cap | $52.9B | $1.1B | |
| P/E as of 2026-10-21 | 58.71 | 49.06 | IRMD lower |
| PEG as of 2026-10-21, 3-year EPS CAGR to FY2025 | n/a | 2.49 | |
| Net margin FY2025, SEC XBRL | +7.7% | +26.8% | IRMD higher |
| Gross margin FY2025, SEC XBRL | n/a | +76.7% | |
| Operating margin FY2025, SEC XBRL | +11.8% | +31.2% | IRMD higher |
| ROE FY2025, SEC XBRL | +6.6% | +23.8% | IRMD higher |
| ROA FY2025, SEC XBRL | +3.0% | +20.7% | IRMD higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.69 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +8.2% | +14.4% | IRMD higher |
| Revenue CAGR (3y) SEC XBRL | +5.0% | +16.3% | IRMD higher |
| Dividend yield as of 2026-09-03 | +2.3% | +1.0% | BDX higher |
| Dividend streak (yrs) SEC XBRL | 13 | 1 | BDX higher |
| Beta as of 2026-09-03 | 0.45 | 0.74 | |
| 1-year return as of 2026-10-21 close | +30.8% | +16.3% | BDX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.